fulranumab monoclonal antibody nerve growth designed treatment johnson johnson licensed drug amgen deal valued around million johnson johnson discontinued phase iii trials fulranumab returned rights originator company said decision based strategic portfolio prioritisation based emerging safety concerns phase iii clinical studies fulranumab osteoarthritic monoclonal article stub help wikipedia expanding analgesicrelated article stub help wikipedia expanding httpsenwikipediaorgwikifulranumab